Jpmorgan Chase & CO Anavex Life Sciences Corp. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 41,374 shares of AVXL stock, worth $302,030. This represents 0.0% of its overall portfolio holdings.
Number of Shares
41,374
Previous 47,909
13.64%
Holding current value
$302,030
Previous $243,000
28.4%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding AVXL
# of Institutions
156Shares Held
26.6MCall Options Held
673KPut Options Held
811K-
Black Rock Inc. New York, NY6.39MShares$46.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.55MShares$33.2 Million0.0% of portfolio
-
State Street Corp Boston, MA3.74MShares$27.3 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.83MShares$13.4 Million0.0% of portfolio
-
Two Sigma Investments, LP New York, NY1.01MShares$7.39 Million0.01% of portfolio
About ANAVEX LIFE SCIENCES CORP.
- Ticker AVXL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,942,800
- Market Cap $569M
- Description
- Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...